The Effect of Neurostimulation on Ischemic Pain and Methods of Assessing Pain by Keck, Kaylee
 THE EFFECT OF NEUROSTIMULATION ON ISCHEMIC PAIN AND METHODS 
OF ASSESSING PAIN 
 
   
 
 
A Senior Project 
presented to 
the Faculty of the Biomedical Engineering Department 
California Polytechnic State University, 
San Luis Obispo 
 
 
 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Bachelor of Science in Biomedical Engineering  
 
by 
Kaylee Keck 
December 2015 
 
 
 
 
PROJECT INFORMATION 
 
TITLE: THE EFFECT OF NEUROSTIMULATION ON 
 ISCHEMIC PAIN AND METHODS OF ASSESSING 
 PAIN 
 
 
AUTHOR: Kaylee Keck 
 
 
DATE SUBMITTED: December 2015 
 
 
 
 
 
 
 
 
ADVISOR:  Trevor Cardinal, PHD 
 Associate Professor of Biomedical Engineering  
 
ADDITIONAL ADVISOR: Melanie Goodman Keiser, PHD 
 St. Jude Medical 
 
ADDITIONAL ADVISOR: Stuart Rosenberg 
 St. Jude Medical 
 
iii 
 
Abstract 
Peripheral arterial disease (PAD) impacts approximately eight million people in the 
United States [1]. Disease progression leads to chronic ischemic pain, hindering quality 
of life. Pharmaceuticals are a typical treatment for pain associated with PAD; but as few 
as 30% of patients have a significant reduction of pain (≥50%) [2]. 
Neurostimulation is commonly used as a treatment for various diseases and injuries, 
including Parkinson’s disease and sports-related back and knee injuries [2]. The objective 
of the study was to explore neurostimulation and its effect on pain and paresthesia for a 
model of acute peripheral ischemia in young college students.  
Pain is highly subjective and as a result can be difficult to measure. As a result, various 
pain scales and questionnaires exist and are commonly used for self-reported 
measurement of pain. Based on literature and prior pilot work, three instruments for 
measuring pain were employed to determine which would provide the best signal to noise 
ratio. Of all the instruments tested, the McGill Pain questionnaire best showed differences 
in pain in this study, with the best signal to noise ratio, and is recommended for future 
research and clinical assessment of ischemic pain.  
Neurostimulation treatment did not cause a statistically significant reduction in pain. 
However, different trends are seen among different patients with some patients having an 
apparent decrease in pain with transcutaneous electrical nerve stimulation (TENS) 
treatment while others have an apparent decrease in pain with interferential currents 
stimulation (IFC) treatment. This indicates that it would be worthwhile to further explore 
neurostimulation and determine what causes the differing responses. Based on the 
differing responses, neurostimulation should be pursued as a method of ischemic pain 
reduction that could be tailored to the specific patient based on what neurostimulation 
best helps them. 
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Chapter 1- Introduction 
1.1 PAD and Ischemia 
Peripheral arterial disease (PAD), also known as peripheral arterial occlusive disease 
(PAOD), is the reduction of blood flow resulting from narrowed or occluded arteries, 
typically associated with atherosclerosis [1]. PAD often results in ischemia, or 
insufficient blood supply, in the limbs and is generally associated with pain [1]. PAD 
initially involves pain only during exercise, described as intermittent claudication, but 
with progression of the disease, patients develop critical limb ischemia, in which they 
experience pain at rest; critical limb ischemia pain associated with progressed PAD is 
mainly neuropathic pain [2, 3]. Neuropathic pain is a type of chronic pain that can result 
when nerve fibers are affected by tissue damage [2]. The nerve fibers may be injured or 
dysfunctional as a result of tissue damage due to lack of blood flow in the case of PAD. 
Unlike nociceptive pain, the intensity of the pain may change throughout the day, but it 
continues throughout the day regardless of activity level [3]. 
1.2 Neurostimulation 
Pain associated with PAD is currently treated using pharmaceuticals, which proves 
insufficient for decreasing pain in as many as 60% of patients [2]. Neurostimulation is a 
non-pharmaceutical treatment to treat pain, including neuropathic pain, which is very 
successful in many other diseases and injuries [2, 4]. Transcutaneous electrical nerve 
stimulation (TENS) is a prevalent type of neurostimulation used to treat many different 
conditions [5]. TENS is a biphasic pulsed current, producing a square waveform [5]. 
TENS changes peripheral nervous system activity causing an analgesic effect and 
paresthesia [4]. Paresthesia is a sensation caused by pressure on peripheral nerves, often 
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described as “pins and needles”, much like when one would feel when one’s foot “falls 
asleep” [4]. Interferential currents stimulation (IFC), is another common form of 
neurostimulation used for various therapeutic applications [6, 7]. IFC uses burst-
modulated alternating sinusoidal currents, which may be more effective at penetrating 
deeper through the skin than TENS [6, 7].The difference in waveform and penetration 
may result in different analgesic effects 
One of the main objectives of the study was to determine if either or both 
neurostimulation modalities reduce pain. 
1.3 Pain Scales 
To determine the efficacy of the neuromodulation approach, pain must be assessed. Pain 
is highly subjective, so assessing pain is challenging; not everyone interprets the same 
pain the same way. Given that pain is so subjective, many different metrics have been 
developed to capture it. There are many techniques used in clinical and research settings 
to assess pain, including pain scales and questionnaires. Numerical Rating Scale (NRS), 
Face Pain Scale (FPS), and the Short Form McGill Pain Questionnaire (MPQ) are 
common tools for pain assessment used in healthcare [8, 9]. The NRS is very basic, 
allowing subjects to rank pain from 0-10 (or in some cases 1-10), with 0 being no pain 
and 10 being the worst pain possible. The FPS uses seven faces to gauge an individual’s 
pain; the FPS used in this study was developed for healthcare professionals and parents to 
aid in the assessment of children’s pain intensity, Appendix D [10]. The short form MPQ 
(henceforward referred to as simply MPQ) was developed by Melzak in 1986 after the 
success of the long version of the McGill Pain Questionnaire, to be used when the longer 
version was not practical [11].  The MPQ has been used in various studies and clinical 
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assessments of chronic ischemic pain associated with PAD [2, 3]. The Questionnaire 
includes 11 sensory descriptive words and 4 affective descriptive words, Appendix E. 
The individual is asked to describe their pain by ranking each word as none (0), mild (1), 
moderate (2), or severe (3). The rankings for each word are added up to provide the MPQ 
pain score.  
In initial pilot work, the NRS scale was used on its own. The resulting pain data provided 
an unclear picture of pain. To get a better idea of what was actually happening with the 
pain, the FPS and MPQ were implemented in further pilot studies. For many, it was 
unclear what each number on the NRS pain scale meant. With the FPS, participants were 
able to visualize their pain, and with MPQ they were able to actually describe what they 
were feeling. The pilot studies including all three pain scales provided a better idea of 
what was happening with pain. 
In pilot work implementing the MPQ, it was found that after treatments, participants 
would on their own describe their feeling of the pain with words commonly used to 
describe paresthesia. So, in order to capture this, paresthesia descriptive words were 
included in addition to the pain words on the MPQ in all subsequent work, Appendix F. 
A secondary objective of the study was to determine the efficacy of the pain scales. 
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Chapter 2- Methods 
2.1 Design 
Several pilot studies were conducted, with 8-12 college students per study, leading up to 
the small-scale pre-clinical study. The small-scale pre-clinical study included 45 college-
age students. Participants volunteered for participation. Each participant completed a 
consent form and a medical-history questionnaire.  
For the small-scale pre-clinical study, participants received compensation, in the form of 
a $25 gift card, if they refrained from consuming caffeine for the 24 hours prior to 
participation.  
The study involved young healthy college students, so to study the effect on ischemia, 
ischemia was induced. This was done by occluding the lower arm of the dominant hand 
with a manual sphygmomanometer for treatments with occlusion. 
There were six treatments: placebo without occlusion (P-), placebo with occlusion (P+), 
TENS without occlusion (T-), TENS with occlusion (T+), IFC without occlusion (I-), and 
IFC with occlusion (I+). A random blocked design was used, in which each participant 
underwent all six treatments in a random order.  
2.2 Experimental Setup and Procedure 
The participants were instrumented to measure blood flow, blood pressure, heart rate, 
respiration rate, hand grip, and skin temperature (All measurements, aside from pain are 
presented in the Master’s thesis by Leah Schafer), Figure 1. A manual 
sphygmomanometer was used to occlude the treatment arm, and a hand dynamometer 
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was used for performing exercise. During the later pilot studies and the small-scale pre-
clinical study, the face pain scale and MPQ/Paresthesia questionnaire words were posted 
on the wall across from the participant (see Appendices D-F for scale and questionnaire). 
After the participant completed the health history and consent forms, Appendices A and 
B, they sat in the medical chair and were instrumented to measure blood flow, blood 
pressure, respiration, and grip strength. The neurostimulation electrodes were placed on 
the participant’s back at the C7 and T4 vertebrae locations, approximately 3 cm to the left 
and right of the vertebral column, Figure 2. For the treatments with TENS or IFC, the 
frequency was set to 100 Hz and pulse duration to 200 μs. The intensity of the 
neurostimulation was increased by increments of one millivolt until the sensory threshold 
Figure 1 Experimental Setup: (A) Hand grip dynamometer gripped in the dominant hand, 
used to perform static hand grip exercises, during exercise phase (B) Optic Laser Doppler 
Flowmetry (LDF) skin probes used to measure blood flow (C) Manual sphygmomanometer 
used for occlusion of dominant arm (D) Automated BP monitor affixed to the upper 
contralateral arm to measure blood pressure (E) TENS/IFC unit (connected to electrodes 
were placed on the upper back_(F) Respiration belt to measure breathing rate (G) 
moorVMS-LDF data acquisition unit, used to collect blood flow (H) PowerLab DAQ 
connected to a laptop (I) Heat thermistor used to measure skin temperature on treatment 
hand (hidden beneath hand dynamometer in picture) 
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was reached, specifically the threshold in which the participant could feel the 
neurostimulation but there was no pain or muscle twitching. 
NRS and FPS pain (Number pain 0-10 and Face A-G) were assessed every minute 
throughout all phases and the McGill Pain/Paresthesia Questionnaire was performed 
halfway through both the exercise and occlusion phase. For the questionnaire, each word 
was read to the participant and the participant was asked to respond “none”, “mild”, 
“moderate”, or “severe” based on the pain they were feeling in their treatment arm.  
Each treatment began by collecting one minute of baseline measurements, then 
progressed to the Exercise stage, in which the maximum strength was determined through 
three maximal contractions lasting 1 second each. The participant then maintained their 
grip on the hand dynamometer at 25±5% of their maximum grip for three minutes. After 
three minutes the manual sphygmomanometer was inflated to 180 mmHg to occlude 
Figure 2 Electrodes Placement on Subject's Back, electrodes 
were placed at C7 and T4 vertebrae 
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blood flow and the participant released the hand grip dynamometer. The cuff was inflated 
for three minutes, before a one minute recovery stage. For treatments without occlusion, 
the manual sphygmomanometer was not inflated. 
The participant was allowed to rest roughly 10-15 minutes between each treatment to 
ensure that they returned to baseline. The protocol was then repeated for each treatment 
in random order for each participant. 
2.3 Statistical Methods 
For the number and face pain data, a binary logistic regression model was used to 
compare differences in pain between TENS, IFC, and placebo. 
The responses for the MPQ/Paresthesia Questionnaire data, were converted into 
numerical form by assigning “none” with 0, “mild” with 1, “moderate” with 2, and 
“severe” with 3. The numerical questionnaire data was analyzed using an ANOVA-
General Linear Model to compare the different treatments.  
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Chapter 3- Results 
3.1 Pilot Studies Results 
The initial objective of the pilot studies was to determine if the pain scale(s) being used 
were adequate to capture the changes in pain, and which pain scale could best do this. 
The follow-up objective was to determine which of the pain metrics was best. 
From the initial pilot studies using only the NRS rating scale, most participants had a 
change of pain of either 0 or 1. The results showed no difference between the 
neurostimulation modalities and their ability to reduce pain compared to placebo. 
Later pilot studies using the FPS and the MPQ pain scales still did not show a significant 
difference in change in pain for TENS or IFC compared to placebo. The MPQ pain scale, 
however, did result in being able to detect larger changes in pain ranging from 1 to 8. 
3.2 Small-Scale Pre-Clinical Study Results  
The main objective of the small-scale pre-clinical study was to determine whether TENS 
or IFC would have an effect on pain, especially during occlusion. A secondary objective was to 
determine the efficacy of the pain scales, specifically the MPQ scale, which pilot work indicated 
to be the best metric. 
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3.2.2 Numerical Rating Scale Results 
During exercise, neurostimulation had a varying effect on change in pain in different 
participants, Figure 3.  Overall, TENS and IFC were both slightly more likely to have an 
increase in NRS pain during exercise as compared to Placebo (Placebo:IFC-odds ratio 
0.7889; IFC:Placebo- odds ratio 1.2905). TENS was very slightly more likely than IFC to 
cause an increase in pain during exercise (TENS:IFC-odds ratio 1.2905). Though none of 
these trends were statistically significant (Figure 4).  
Figure 3 Line Plot of Mean Change in NRS Pain during the Exercise Phase, for each participant 
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During the next phase of the experiment, occlusion, the trends change in NRS pain varied 
widely by participant, as it did in the exercise phase, Figure 5.  Placebo treatment is 
slightly more likely than the IFC treatment to have an increase in pain during occlusion 
Figure 5 Main Effects Plots for Change in Pain during the Exercise Phase 
Figure 4 Line Plot of Mean Change in NRS Pain during the Occlusion Phase for each Participant 
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(odds ratio of 1.1438). TENS is slightly less likely to have an increase in pain during 
occlusion than both IFC and Placebo (odds ratios T:I 0.7294 and T:P 0.6377, Figure 6. 
Treatments with ischemia are much more likely to have an increase in pain than 
treatments without ischemia (odds ratio with occlusion (+): without occlusion (-) is 
9.1261), Figure 6.  The difference between with and without ischemia was significant. 
The differences between neurostimulation were not significant.  
3.2.3 Face Pain Scale Results 
The Face Pain Scale data varies greatly by participant, Figure 7. Placebo is slightly more 
likely than both IFC and TENS to have an increase in FPS score during exercise (odds 
ratios P:I 1.2286 and T:P 0.8617). TENS is slightly more likely than IFC to have an 
Figure 6 Main Effects Plot for Change in NRS Pain during the Occlusion Phase 
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increase in FPS pain during exercise (odds ratio T:I 1.0587). These relationships between 
neurostimulation, Figure 8, are not statistically significant. 
 
Figure 7 Line Plot of Mean Change in Face Pain during the Exercise Phase 
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Similarly to the exercise phase, the occlusion phase shows great variability between 
participant changes in pain with different neurostimulation, Figure 9. Placebo is slightly 
less likely than both TENS and IFC to have an increase in FPS Pain during the occlusion 
Figure 9 Line Plot of Mean Change in Face Pain during the Occlusion Phase, for each participant 
Figure 8 Main Effects Plot for Change in Face Pain during the Exercise Phase 
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phase (odds ratios P:I 0.7275 and T:P 1.3158). TENS is very slightly less likely to have 
an increase in FPS during occlusion than IFC (odds ratio T:I 1.9572). These trends in 
neurostimulation were not statistically significant, Figure 10. Treatments with ischemia 
are considerably more likely to have an increase in pain than treatments without ischemia 
(odds ratio 8.5105). The significant difference between with and without ischemia is 
illustrated by the steep slope in the ischemia panel of the Main Effects Plot, Figure 10. 
3.2.4 McGill Pain Questionnaire plus Paresthesia Questionnaire 
The results of McGill Pain and Paresthesia Questionnaires scores together during the 
exercise phase showed that participant change in pain varied significantly (p-value 
0.000). Neither ischemia nor neurostimulation affected reported pain during the exercise 
phase (p-values of 0.288 and 0.539 respectively). These results are illustrated by the Main 
Effects plot, Figure 11, which shows that the points for the different participants vary a 
great deal, whereas the points for IFC, TENS, and Placebo for neurostimulation in the 
upper right panel, and with and without ischemia in the lower left panel are relatively the 
Figure 8 Main Effects Plot for Change in Face Pain during the Occlusion Phase 
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same. The interaction between ischemia and neurostimulation was also not statistically 
significant (p-value of 0.078), Figure 12.   
Again, during the occlusion phase, the MPQ and Paresthesia data show participant to be 
significant with a great deal of variability (p-value of 0.000). Ischemia does have a 
significant effect on change in pain during the occlusion phase, with treatments with 
ischemia having an increase in pain compared to without (p-value of 0.000). 
Neurostimulation does not have a significant effect on the change in MPQ and 
Figure 9 Interaction Plot for MPQ plus Paresthesia during the Exercise Phase 
Figure 10 Main Effects Plot for MPQ plus Paresthesia during the Exercise Phase 
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Paresthesia score during occlusion (p-value of 0.630).  These results are illustrated by the 
main effects plot, Figure 13. Participant varies in an irregular manner and ischemia has a 
steeply sloped line with (+) ischemia higher than (-) ischemia.  Neurostimulation again 
has values that are relatively unchanged. The interaction between neurostimulation and 
ischemia is again not significant (p-value of 0.126), illustrated by the similarly sloped 
lines in the interaction plot in Figure 14. 
Figure 11 Main Effects Plot for MPQ and Paresthesia during the Occlusion Phase 
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3.2.5 McGill Pain Questionnaire Pain Score 
The MPQ score data on its own shows variability by participant during the exercise phase 
as well (p-value of 0.000), Figure 15. Neither ischemia nor neurostimulation 
significantly affect the change in MPQ pain only during the exercise phase (p-values 
0.063 and 0.897 respectively), Figure 16. Tukey confidence intervals illustrate this as 
Figure 12 Interaction Plot for MPQ plus Paresthesia during the Occlusion Phase 
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well in Figures 17 and 18, since all intervals include 0 the factor levels are not 
significantly different.   
 
Figure 13 Line Plot of Mean for MPQ Pain Scores during the Exercise Phase 
Figure 14 Main Effects Plot for MPQ Pain Scores during the Exercise Phase 
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Figure 16 Tukey Confidence intervals for the Difference of Means between Neurostimulation 
modalities for MPQ Pain Scores during the Exercise Phase 
Figure 15 Tukey Confidence Intervals for Difference of Means between with and without 
Ischemia for MPQ Pain Scores during the Exercise Phase 
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The interaction between ischemia and neurostimulation is not statistically significant, 
Figure 19.The MPQ score data during occlusion ranges by participant as well, Figure 
20.  Both participant and ischemia have a significant effect on change in MPQ pain score 
during occlusion (p-values of 0.000). Neurostimulation does not significantly change the 
 
Figure 18 Interaction Plot for MPQ Pain Score during the Exercise Phase 
Figure 17 Line Plot of Mean MPQ Pain Score by subject during the Occlusion Phase, for each participant 
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MPQ-assessed pain during occlusion (p-value 0.918), Figure 21.  The interaction 
between ischemia and neurostimulation is also not significant during occlusion (p-value 
0.104), Figure 22. 
3.2.6 Paresthesia Questionnaire Score 
Like the MPQ pain scores, paresthesia score varied by participant, Figure 23.  
Figure 19 Interaction Plot for MPQ Pain Score during the Occlusion Phase 
Figure 20 Main Effects Plot for MPQ Pain Score during the Occlusion Phase 
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 Paresthesia Questionnaire scores during the exercise phase are significantly affected by 
participant and neurostimulation (p-values 0.000 and 0.022 respectively), Figures 24 and 
25. TENS increases paresthesia more than placebo during exercise, Figure 25.  
Figure 22 Line Plot of Mean Paresthesia Score during the Exercise Phase, for each participant 
Figure 21 Main Effects Plot for Paresthesia during the Exercise Phase 
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The interaction between neurostimulation and ischemia is not statistically significant (p-
value of 0.075), Figure 26.  
Participant also causes variation in Paresthesia during the occlusion phase (p-value 
0.000), Figure 27. During occlusion, ischemia significantly affects the change in 
paresthesia (p-values of 0.000), Figure 28. Neurostimulation does not significantly affect 
Paresthesia during occlusion (p-value 0.238). The interaction between ischemia and 
Figure 24 Tukey Confidence Interval for Difference of Mean Paresthesia Score between 
Neurostimulation modalities during the Exercise Phase 
Figure 23 Interaction Plot for Paresthesia during the Exercise Phase 
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neurostimulation is not significant during occlusion as with exercise, (p-value of 0.080), 
Figure 29.  
 
 
Figure 25 Line Plot of Mean Paresthesia Score during the Occlusion Phase, for each participant 
Figure 26 Main Effects Plot for Paresthesia during the Occlusion Phase 
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Figure 27 Interaction Plot for Paresthesia score during the Occlusion Phase 
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Chapter 4- Discussion 
The objectives of this study were to determine the best way of assessing pain and to 
determine if either TENS or IFC neurostimulation modalities affect acute ischemic pain. 
The MPQ appears to be a better way of assessing the pain caused in this study. A larger 
difference in pain can be seen, whereas with the NRS and Face pain scales the differences 
in pain detected were small, typically between 0 and 1. For future work, the MPQ would 
be recommended for the assessment of pain. 
The results of the data provided by the pain scales indicate that neither TENS nor IFC 
induce analgesia during either the exercise or occlusion. This may result from the study 
being done with all young, healthy participants, in which there was not enough pain to be 
able to detect significant changes in pain. 
TENS did increase paresthesia during the exercise phase. This may be due to the way in 
which TENS interacts with the nervous system. Future research could explore this effect. 
Although TENS or IFC neurostimulation did not generally induce analgesia, the 
variability between participants suggests that TENS may be efficacious in some patients, 
while IFC may be better for others. This may be due to differences between participants, 
whether due to individual physiology, gender, athleticism, or other unknown factors. 
Further work would include additional replicates and an emphasis on examining different 
factors to explore what causes the differing trends between participants.  
Due to many participants never reporting any pain, likely due to the use of young, healthy 
participants, further studies should be conducted with individuals who actually suffer 
from PAD or other diseases causing ischemic pain, and on people from varying age 
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groups. In a study with participants who have the disease, there would be a higher 
amount of pain and thus differences in pain would be more easily detected. With 
differences in pain more easily detected, a trend may become clearer.
28 
 
Conclusion 
The results indicated that the MPQ makes it easier to view changes in pain for this type 
of simulated pain study than NRS or FPS; the large difference in the pain detected by this 
study lead to the recommendation that MPQ be used either in place of or in addition to 
the other scales in the assessment for self-reporting pain.  
This study did not show neurostimulation to be statistically significant, therefore, 
evidence was not found to show that neurostimulation significantly reduces ischemic pain 
in young college students. However, different trends were shown in different participants, 
which indicate trends toward neurostimulation affecting pain, though differently in 
different participants. This leads to the desire for future work to explore the differences in 
participants that lead to the differences in effects of neurostimulation. In addition, 
neurostimulation may be further explored as a treatment for ischemic pain reduction, 
which would need to be personalized for the individual.  
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Appendices 
Appendix A: Informed Consent Form 
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Appendix B: Medical History Questionnaire 
MEDICAL HISTORY 
*= Required 
General Information 
Participant: 
Name: ___________________________________________________________________________ 
Contact phone number(s): ___________________________________________________________ 
Age: _________________________________ 
Height: _______________________________ 
Weight: _______________________________ 
Dominant Hand:  □ Right □ Left 
Sex: 
□ Male □ Female 
Women only answer the following: 
Yes No 
□ □     *Are you currently pregnant? 
□ □     Are you currently breast-feeding? 
Men and women answer the following: 
Have you consumed caffeine in the last 12 hours?  □ Yes □ No 
Have you exercised to 50% of your maximum heart rate (moderate exercise) in the last: 
 48 hours?  □ Yes  □ No 
 12 hours?  □ Yes  □ No 
List any prescription medications you are currently taking:  
_____________________________________________________________________________________ 
Do you have any implantable electrical devices (pacemaker, implantable cardioverter defibrillator, etc.)?       
  □ Yes     □ No       If yes, please list: 
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_____________________________________________________________________________________ 
In the past two months, have you experienced any major injury or significant trauma to your arms or upper 
back?        □ Yes     □ No       If yes, please describe: 
_____________________________________________________________________________________ 
Past Medical History 
Have you ever experienced any of the following: 
Yes No 
□      □   Heart attack 
□ □   High blood pressure (hypertension) 
□ □   Rheumatic Fever 
□ □   Heart murmur (abnormal heart sound) 
□ □   Arrhythmia (irregular heartbeat) 
□ □   Diseases of the arteries (peripheral artery disease, coronary artery disease, etc.) 
□ □   *Epilepsy or seizures 
□ □   Varicose veins (twisted, enlarged veins) 
□ □   Diabetes or abnormal blood sugar 
□ □   Phlebitis (inflammation of the veins) 
□ □   Stroke 
□ □   Anemia (low red blood cell count) 
□ □   *Dermatitis/eczema (inflammation of the skin) 
□ □   *Pain or tingling sensations in your limbs 
□ □   *Syncope (fainting) 
Smoking 
Have you ever smoked tobacco?         □ Yes □ No 
If yes, how long did you smoke OR how long have you been smoking? _________________________ 
How frequently did/do you smoke? ___________________________ 
Drinking 
On average, do you drink more than 1 alcoholic beverage per day?         □ Yes        □ No 
Do you have a past history of heavy drinking?        □ Yes        □ No 
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Appendix C: Protocol 
PROTOCOL FOR STUDY 
I. Setup  
1. Turn on the laptop. 
2. Connect the power supply to PowerLab.   
3. Connect the USB cable from PowerLab to the laptop.   
4. Connect the respiration belt to Input 1 on the front panel of PowerLab.  
5. Connect the Hand Dynamometer to Input 2 on the front panel of PowerLab.   
6. Connect the power supply to the Laser Doppler Flow (LDF) system and turn it 
on.   
7. Connect the skin probes to Channels 1 and 2 on the LDF system.  
8. Connect the BNC cables from the LDF system to Inputs 3 and 4 on the front 
panel of PowerLab.   
9. Turn on the PowerLab system.  
10. Open LabChart on the laptop and open the customized settings file.  
i. The raw breath signal in millivolts (mV), the respiratory rate in breaths 
per minute (BPM), the handgrip force in Newtons (N), CBF 1 in 
perfusion units (PU), and CBF 2 in PU should all be displayed in 
LabChart at this point.   
II. Application  
1. Seat the participant in a chair with both arms supinated and gently resting on the 
tray. Ensure that they are comfortable and properly positioned before continuing.   
2. Apply the electrodes to the C7 and T4 vertebrae locations, approximately 3 cm to 
the left and right of the vertebral column (Figure 1).†  
3. Wrap the respiration belt around the participant’s chest, just below the xiphoid 
process.  
4. Attach the skin probe connected to Channel 1 of the LDF system to the left arm, 
2 cm below the crease of the wrist.   
5. Attach the skin probe connected to Channel 2 of the LDF system to the right arm, 
2 cm below the crease of the wrist.   
6. Wrap the cuff connected to the manual sphygmomanometer around the 
participant’s left forearm, 2 cm below the crease of the elbow.  
7. Wrap the cuff connected to the blood pressure monitor around the participant’s 
right arm. 
8. Instruct the participant to loosely grip the Hand Dynamometer in their dominant 
hand.   
9. Instruct the participant to squeeze the Hand Dynamometer as hard as possible for 
a second or two, and then relax their grip.*  
10. Determine Maximum Voluntary Contraction (MVC) by recording the average of 
three handgrip trials and calculate 25% of MVC. 
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TENS Electrode Placement at the C7 and T4 Regions* 
III. Treatment  
1. Begin treatment according to assigned group code.†  
2. Every minute, assess the intensity of the participant’s pain via the NPRS. In 
addition, halfway through each interval of the treatment i.e. “baseline”, 
“exercise”, “occlusion”, and “recovery”, record the participant’s blood pressure 
and heart rate from the monitor.  
3. Set the stimulation frequency to 100 Hz, pulse duration to 200 μs, and slowly 
adjust the intensity to just above sensory threshold (no pain or muscle 
contraction) by asking the participant when he/she begins to feel a strong, but 
comfortable tingling sensation. 
4. Begin 1 min metronome and instruct participant to verbalize his or her pain level 
every min. 
5. Begin 1.5 min metronome and collect BP & HR data every 1.5 min. 
6. Begin recording baseline blood flow for 3 minutes at resting heart rate. 
7. Place the hand dynamometer in the participant’s left hand. Instruct the participant 
to perform a static handgrip exercise for 3 minutes at 25% MVC.  
8. Five seconds before exercise completion, inflate the sphygmomanometer cuff to 
180 mmHg.! 
9. Maintain cuff inflation at 180 mmHg for 3 minutes, while still recording blood 
flow.   
10. Deflate the cuff immediately and record for 3 minutes.  
11. Stop recording.   
12. Insert comments for “baseline”, “exercise”, “occlusion”, and “recovery” at the 
end of each interval.   
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13. Detach all equipment from the participant and wait at least 10 minutes before 
beginning the next treatment.    
 
 
 
 
* Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy young and older subjects." 
by Vieira, et. al. 
† Group codes: Placebo/PECO- (P-), Placebo/PECO+ (P+), TENS/PECO- (T-), TENS/PECO+ (T+), IFC/PECO- (I-), IFC/PECO+ 
(I+) 
! Only if PECO+ group 
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Appendix D: Face Pain Scale [14] 
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Appendix E: McGill Pain Questionnaire [11] 
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Appendix F: Paresthesia Questionnaire 
 
